Sign in
Taking people in BelgiumPhase 4

Clindamycin levels in adults with bone, joint implant or skin infections

Measures clindamycin levels in adults, looking at body weight and rifampicin use.

Key facts

Who runs it
UZ Leuven
Where
Leuven, BelgiumSee the site
Registry title
Clindamycin for the treatment of infections: the influence of rifampicin and obesity on PK/PD target attainment
Status
Recruiting
Phase
Phase 4
People taking part
40 people, planned
Started
29 Jul 2025
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are starting clindamycin for an infection, alone or together with rifampicin. Conditions include bone fracture infections, joint replacement infections and hidradenitis suppurativa. It studies how body weight and rifampicin change clindamycin levels in the body.

Age
18 years or older
Sex
All sexes
Disease stage
Groups by body weight: BMI < 30 (Cohort 1&3) or BMI ≥ 30 (Cohort 2&4).
Earlier treatment
People must be starting clindamycin alone (Cohort 1&2) or clindamycin with rifampicin (Cohort 3&4). No use of CYP3A4 inducers in the last 2 weeks, or CYP3A4 inhibitors in the last 5 days.

Main reasons for not taking part

  • Past allergic reaction to clindamycin or rifampicin
  • Pregnant, breast-feeding, planning pregnancy, or able to get pregnant without highly effective birth control
  • Liver damage with a Child Pugh score of 7 or higher
  • Taking part in another trial with a test drug or device
  • Other illnesses or treatments that could make the trial unsafe

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • At least 18 years of age at the time of signing the Informed Consent Form (ICF)
  • Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner
  • A BMI < 30 (Cohort 1&3) or BMI ≥ 30 (Cohort 2&4)
  • Initiation of clindamycin monotherapy (Cohort 1&2) or initiation of clindamycin/rifampicin combination therapy (Cohort 3&4)

Who cannot take part

  • Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial
  • Recent (2 weeks) or concomitant use of CYP3A4 inducers
  • Recent (5 days) or concomitant use of CYP3A4 inhibitors
  • Participant has a history of allergic reaction to clindamycin or rifampicin
  • Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
  • Liver impairment as defined by a Child Pugh score 7 or higher at baseline
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive
  • Participation in an interventional Trial with an investigational medicinal product (IMP) or device

Where in Belgium

  • UZ LeuvenLeuven, BelgiumTaking people

About the trial

What the trial wants to find out

The aim of the trial is to investigate the exposure to clindamycin and the influence of body weight and concomitant rifampicin treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Clindamycin for the treatment of infections: the influence of rifampicin and obesity on PK/PD target attainment
Plain-language title
Clindamycin levels in adults with bone, joint implant or skin infectionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
16 July 2026